Participated · Series D · May 2026

Full-Life is a clinical-stage radiotherapeutics company with a discovery platform called UniRDC™ that has produced multiple pipeline programs. Its lead and pipeline assets include potential best-in-class [225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. The company plans to have three differentiated clinical-stage programs by the end of 2026 and to bring GMP-grade 225Ac manufacturing online at its Belgium facility to control isotope supply and production. Financially, Full-Life announced a US$150 million financing in 2026 (approximately US$110 million Series D equity and US$40 million debt) and has raised nearly US$350 million since founding in 2021. The company operates globally with locations referenced in Suzhou, China and Gembloux, Belgium.